Histone modifications are important for maintaining the transcription program. BET proteins, an important class of "histone reading proteins", have recently been described as essential in bone biology. This study presents the therapeutic opportunity of BET protein inhibition in osteoporosis. We find that the pharmacological BET protein inhibitor JQ1 rescues pathologic bone loss in a post-ovariectomy osteoporosis model by increasing the trabecular bone volume and restoring mechanical properties. The BET protein inhibition suppresses osteoclast differentiation and activity as well as the osteoblastogenesis in vitro. Moreover, we show that treated non-resorbing osteoclasts could still activate osteoblast differentiation. In addition, specific inhibition of BRD4 using RNA interference inhibits osteoclast differentiation but strongly activates osteoblast mineralization activity. Mechanistically, JQ1 inhibits expression of the master osteoclast transcription factor NFATc1 and the transcription factor of osteoblast Runx2. These findings strongly support that targeting epigenetic chromatin regulators such as BET proteins may offer a promising alternative for the treatment of bone-related disorders such as osteoporosis.
Introduction
Bone is a dynamic tissue in constant change through a physiological remodeling process involving bone-specific cells; the osteoclasts which are responsible for the resorption of old or damaged bone and the osteoblasts which are specialized in the formation of a new bone [1, 2] . In physiological conditions the balance between bone resorption and bone formation is required to maintain constant bone mass for the majority of adulthood.
Disruption of this physiological balance leads to the development of bone-related disorders.
Osteoporosis is the most prevalent bone disease in older women and men, characterized by a low bone mass, reduced bone mineral density, and deterioration of bone microarchitecture leading to an increased fracture risk. In osteoporosis the rate of bone resorption exceeds the rate of bone formation, thus decreasing the bone mass [1] . Currently, most available agents in clinical use to treat osteoporosis inhibit bone resorption, whereas only a few stimulate bone formation and restore bone mass [3] .
Recent molecular and genetic studies, identifying numerous local and systemic regulators of bone resorption, have considerably improved our molecular knowledge of bone remodeling [4] . Amongst them, epigenetic regulation which include posttranslational histone modifications, miRNA-mediated post-transcriptional regulation and DNA methylation play an important role in bone biology [5, 6] .
Bromodomain and extra-terminal domain (BET) protein family (BRD2, BRD3, BRD4, and BRDT), through its ability to bind to acetylated lysine on histone tails, is an important class of "histone reading protein" [7] . Bromodomains act as a scaffold for molecular complexes at the recognized histone sites in order to regulate chromatin accessibility to transcription factors and RNA polymerase [8] . Recently, several BET protein inhibitors have been developed including JQ1 and I-BET151. They were described as a new
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4 therapeutic approach in various preclinical cancer models [9] [10] [11] [12] [13] . In addition, these smallmolecule inhibitors of BET proteins were recently identified to suppress bone destruction in many distinct inflammatory diseases (arthritis, periodontitis, bone tumour, osteoporosis) [11, [14] [15] [16] .
In this study, we confirm the therapeutic potential of BET protein inhibition, by using JQ1, to reverse bone loss induced by estrogen deficiency. Morever, our findings deepthly demonstrate that JQ1 rescues bone mass and bone strength in ovariectomy-induced osteoporotic mice by interfering with osteoblast and osteoclast differentiation. We observed that JQ1 treated-osteoclasts could still activate osteoblastogenesis in vitro. Importantly, we provide evidence that BET protein inhibition does not affect the structure and mechanical properties of bone in physiological conditions. These findings reinforce the therapeutic potential of BET protein inhibition in diseases characterized by an impairment of bone formation.
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Materials and Methods

Therapeutic agents
The BRD4 inhibitor, JQ1, was kindly provided by James Bradner (Dana-Farber Cancer Institute) and used for in vitro and in vivo studies. This synthetic compound selectively targets the acetyl-lysine binding pocket of BET proteins. For the in vitro studies, JQ1 was dissolved in dimethyl sulfoxide (DMSO) at 10mM stock solution and stored at -20°C. For the in vivo studies, JQ1 was dissolved in DMSO at 50mg/ml, and then diluted in 10% hydroxypropyl beta cyclodextrin (HP--CD, Sigma Aldrich) to obtain the final concentration, 50 mg/kg, and stored at 4 o C. The 10% HP--CD was prepared in sterile water, which was filtered with 0.22 micron filter.
Animal Treatment
All procedures involving mice [their housing in the Experimental Therapeutic Unit at the Faculty of Medicine of Nantes (France) and care, the method by which they were anesthetized and killed, and all experimental protocols] were all conducted in accordance with the institutional guidelines and were approved by the "Ethic Committee for Animal Experimentation" (CEEA.PdL. Licence : 2011.32). 8-week old C57BL/6 female mice ovariectomized (OVX) or SHAM-operated (SHAM) from Janvier Labs (Le Genest-Saint-Isle, France), were left untreated for 2 weeks, and then treated with JQ1 (50 mg/kg) or vehicle (n=6 for each group), twice a day by intraperitoneal (I.P.) injection. In a second experiment, 6-week old C57BL/6 male mice (Janvier labs) were treated with JQ1 (50 mg/kg) or vehicle twice a day by I.P. injection (n=6 for each group). For dynamic bone histomorphometry, mice were injected (I.P.) with calcein (20 mg/kg) at 7 days and 2 days before sacrifice. At sacrifice, the femurs, tibiae and vertebrae L4 were collected for further analysis.
Micro Computed Tomography (microCT) Analysis.
Micro computed tomography (microCT) analysis was performed as previously described [3] .
Briefly, tibias were scanned using high-resolution microcomputed tomography (Skyscan 1076, Kontich, Belgium) at 50kV and 200 A using a 0.5 mm aluminium filter and a detection pixel size of 9µm. Images were captured every 0.7° through 180° rotation, and analysed using Skyscan software. Trabecular structures positioned 0.2 mm below the growth plate, were quantified over a length of 1mm. Cortical bone positioned 1 mm below the growth plate, was quantified over a length of 1mm. For the lumbar vertebra L4, the central 60% of the trabecular bone was analysed. Bone volume/total volume fraction (BV/TV), trabecular thickness (Tb.Th.), trabecular separation (Tb.Sp.), trabecular number (Tb.N.) and Cortical thickness (Ct. Th) were determined.
Bone Histomorphometric Analysis
Tibias were decalcified with 4.13% EDTA and 0.2% paraformaldehyde in phosphate buffered saline (PBS) for 96 hours using the KOS microwave histostation (Milestone, Kalamazoo, MI) before embedding in paraffin. Sections (3 m thick, Leica Microsystems) were analyzed by tartrate-resistant acid phosphatase (TRAP) staining as described previously [17, 18] .
Immunostaining for Osterix was performed as described [17] For undecalcified histology, tibias were methylmethacrylate-embedded for microtome sectioning (6 m) for von Kossa staining.
For the dynamic histomorphometry, tibia were dissected and embedded in methylmethacrylate as previously described [3] . Thin sections were mounted unstained and analysed using an image analysis software program (Qwin) interfaced with a microscopy
using a DMRXA epifluorescent microscope (Leica). All comparisons of staining intensities were made at 200x magnifications.
Three Point Bending
Bones were subjected to three point bending analysis using a Bose Electroforce 3200 mechanical testing machine with a 450 N load cell. Rounded supports and press head were used with a constant span support distance of 6 mm for all femurs. Bones were positioned horizontally with the press head contacting the midshaft. A preload of 0.25 N was applied to the bone before compressing at a constant force of 0.25 N/sec until failure. From the forcedisplacement curve, stiffness (N/mm) was calculated from the linear region and maximum load from the peak force.
Osteoclast Differentiation
Generation of osteoclasts from human CD14 + monocytes was described previously [19] .
Briefly, purified CD14 + cells from different donors were cultured in -MEM with 10% FCS and 25 ng/ml human M-CSF (R&D systems). After 4 days of culture, 100ng/ml RANKL was added. Multinucleated cells formed with 3 nuclei and more were counted after TRAP staining (Sigma, France). The resorption capacity was assessed on 96-well Corning Osteo Assay ®.
Mature osteoclasts were cultured with 25 ng/mL hMCSF, 100 ng/mL RANKL and JQ1 at various concentrations. After 3 days of culture, cells were removed with bleach solution and resorption pits area was quantified using Image J software (NIH, Bethesda, MD).
Osteoblast Differentiation
Before passage 5, human MSCs were seeded at 10 4 cells per centimeter square in 96-well plates in DMEM supplemented with vitamin D3 (10 −8 M; Hoffmann-La Roche, Basel, Switzerland), dexamethasone (10 −8 M; Sigma) and with or without JQ1 as indicated (this represented day 0 for MSC osteogenic differentiation). Three days later, freshly prepared ascorbic acid (50 g/ml; Sigma) and -glycerophosphate (10 mM; Sigma) was added to allow
mineralization, this medium being changed every 2-3 days. Alizarin red-S staining was used to detect the mineralized nodules formed in vitro as described previously [20] . Briefly, between day 19 and 21, cells were fixed in ice-cold 70% ethanol for 1 hour and incubated with Alizarin red-S (40mM, pH 7.4; Sigma) for 10 minutes at room temperature. After extensive washing, images were captured using a stereo microscope (Stemi 2000-C; Zeiss, Oberkochen, Germany), and mineralized surfaces were quantified using the Qwin software (Leica, Nussloch, Germany).
Quantitative Reverse Transcription-PCR
Total RNA was extracted from cultured cells using TRIreagent (Invitrogen Life Technologies). Total RNA was reversed transcribed using the ThermoScript RT-PCR System (Life Technologies). Real-time monitoring of PCR amplification of complementary DNA (cDNA) was performed using DNA primers (primers sequences are available upon request) on CFX96 real-time PCR detector system (Bio-Rad, Marnes la Coquette, France) with SYBR PCR Master Mix buffer (Bio-Rad). Target gene expression was normalized to GAPDH levels in respective samples as an internal standard, and the comparative cycle threshold (Ct) method was used to calculated relative quantification of target mRNAs. Primers for each gene are described in Supplemental Information. Each assay was performed in triplicate.
Gene silencing
Knock-down of BRD2, BRD3, and BRD4 using short hairpin RNA (shRNA) in human preOCs and human MSCs cells were obtained by lentiviral cell transduction as described previously [21] . They were used for lentivirus production following the protocols provided with the ViraPower Lentiviral Expression System (Invitrogen). A multiplicity of infection of 10 was used to transduce MSCs cells and of 4 was used to transduce pre-OCs cells. shRNA targeting LacZ was used as a control.
Statistical Analysis
Data were tested for normality using a Kolmogorov-Smirnov test. The mean ± SEM was calculated for all groups and compared by two-tailed paired Students t test or by ANOVA, with the Dunnett's multiple comparisons test for post-hoc analysis. p < 0.05 was used as the criteria for statistical significance.
Results
BET protein inhibition rescues osteoporosis in ovariectomized mice
We first examined whether a BET protein inhibitor, JQ1, could increase bone mass in ovariectomized mice with established bone loss. We left SHAM-operated or ovariectomized (OVX) 8-week-old mice without treatment for 2 weeks to notice a significant bone loss, then treated them with vehicle or JQ1 (50 mg/kg twice per day) for 4 weeks ( Figure 1A ). Von
Kossa stained cross sections and micro-computed tomography ( CT) analysis of the metaphyseal region of the proximal tibia confirmed the expected trabecular bone loss caused by ovariectomy (34% of trabecular bone volume decrease compared with SHAM, P < 0.001) before treatment ( Figure 1A and figure 1B). After 4 weeks of JQ1 treatment, trabecular bone volume was higher than in OVX mice treated with vehicle (125%, P < 0.001) and SHAMoperated controls (68%, P < 0.01; Figure 1B ). The increase in trabecular bone volume was associated with greater trabecular number and trabecular thickness (respectively +106%, P < 0.001 and +9%, P < 0.05) and lower trabecular separation (-34%, P < 0.001; figure 1B ).
Three-point bending of the left femoral diaphysis was performed to test bone strength.
Ovariectomy without treatment resulted in lower stiffness (-14.3%, P < 0.05, Figure 1C ) and maximum load (-5.4%) compared to SHAM-operated control mice. JQ1 treatment of OVX mice resulted in greater bone strength, with a higher stiffness (17.7%, P < 0.05, Figure 1C ). These results demonstrate that JQ1 treatment strongly reverses an established osteopenia induced by ovariectomy.
BET protein inhibition blocks osteoclast differentiation and activity
To understand the mechanisms responsible for the correction of osteopenia in OVX mice, we figure 2C ). This inhibition of osteoclast formation and activity came with a strong reduction of tartrate-resistant acid phosphatase (TRAP, 80%) and cathepsinK (Ctsk, 87%) expression, two markers of OC differentiation and activity ( Figure 2D ).
To identify the underlying mechanism of JQ1-mediated inhibition of OC differentiation, we then tested the activity of NF-kB using a luciferase-based reporter construct containing its consensus-binding site. Cells expressing RANK were transfected with the NF-kB promoter construct and were then treated with RANKL or TNF in the presence or absence of JQ1. Our results showed that the inhibition of BET proteins by JQ1 treatment reduced RANKL-and
TNF -stimulated NF-kB transcriptional activity (respectively more than 30% and 40%, supplementary figure S1). These findings are sustained by the decrease of NF-kB target genes NFATc1 and MMP9 mRNA expression (respectively 92% and 34%, figure 2D ) in JQ1-treated OC precursors. Our findings demonstrate that inhibition of BET proteins disrupt both OC formation and activity.
Specific inhibition of BRD2, BRD3 and BRD4 recapitulate JQ1 inhibition of osteoclast differentiation in vitro
To make sure the inhibition of the BET proteins was the key mechanism behind the observed effect of JQ1 on osteoclastogenesis, we transduced pre OCs (CD14 + cells) with a combination of shBRD2, shBRD3 and shBRD4 (shBRDs). The knock-down of BRD2, BRD3, and BRD4
were validated at mRNA levels 2 days after transduction ( Figure 3A ). The efficiency of three different shRNA for the BRDs was previously validated on human mesenchymal stem cells (hMSCs) (Supplementary Figure S2 ).
Transduced pre OCs were then cultured with RANKL to induce their differentiation. After 7 days of culture in differentiation medium, shBRDs-transduced cells did not differentiate into
OCs while pre-OCs transduced with shLacZ were still able to differentiate into OCs. It is associated with a reduction of relative expression of hNFATc1 and hMMP9 (respectively 90% and 66%, figure 3B ). This confirmed that the simultaneous inhibition of the three BRDs recapitulates the effects of JQ1 on osteoclastogenesis.
Pre OCs were then transduced with shRNAs specific for BRD2 or BRD3 or BRD4. In these conditions, we observed the same effects that we previously described with a combination of three shBRDs. The silencing of BRD2, BRD3 or BRD4 led to a decrease in osteoclast formation (respectively 95%, 90% and 92%) and to an inhibition of NFATc1 and MMP9
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BET protein inhibition decreases osteoblast differentiation in vitro
The effects of BET protein inhibition on osteoblastic differentiation have been tested using Figure 4B ). We then examined the expression of a critical transcription factor for OB differentiation, RUNX2, and a late stage marker of osteoblastogenesis, ALP. In both cases, JQ1 treatment led to a significant decrease of their gene expression ( Figure 4B ).
Second, to evaluate when the expression of the BET proteins is the most critical to OB differentiation, the same experiments were repeated with a JQ1 treatment only applied during the last 7 days of the differentiation protocol. Similar effects to the first experiment were observed in terms of inhibition of mineralization and RUNX2 and ALP expression ( Figure   4C ). As suggested by Figure 4A , the BET proteins expression in the last steps of the OB differentiation is of utmost importance.
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
14
Considering the resulting increase in bone mass in OVX-mice treated with JQ1 and the direct effects of JQ1 observed on osteoblasts and osteoclasts, we next asked whether JQ1 could interfere into the osteoclast-osteoblast crosstalks and promotote bone formation. We investigated in vitro the activity of preosteoclasts (pre OCs) and osteoclasts (OCs) treated with JQ1 on the differentiation of mesenchymal stem cells into osteoblasts. We revealed that in both case, JQ1 did not modify the ability of pre OCs and OCs to activate osteoblastogenesis as suggested by the expression of hRunx2 ( Figure 4D and supplementary figure S3 ).
Inhibition of BRD2, BRD3 and BRD4 recapitulates JQ1 inhibition of osteoblast differentiation in vitro
To confirm that BET proteins are involved in osteoblast differentiation, human MSCs were cultured in OB differentiation medium and transduced with a combination of shBRD2, shBRD3, shBRD4 (shBRDs). After 3 days, expression of BRD2, BRD3, and BRD4 RNA was assessed by qRT-PCR to validate the efficiency of the shRNAs ( Figure 5A ). After 21 days of culture, mineralization quantification by alizarin red staining and quantification of RUNX2 expression revealed a significant inhibition of OB differentiation by shBRDs compared to shLacZ and confirmed that the simultaneous inhibition of the three BRDs recapitulates the effects of JQ1 on OB differentiation ( Figure 5B ).
Similarly to the experiments performed on osteoclasts, we asked the question whether BRD2, BRD3 and BRD4 are individually essential for osteoblastogenesis. hMSCs were transduced with shRNAs specific for BRD2, BRD3 or BRD4. Interestingly, silencing of BRD2 or BRD3 reduced the extent of OB differentiation as suggested by a reduction of the mineralized area and hRUNX2 expression, whereas the transduction of hMSCs with shBRD4 had the opposite
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15 effect ( Figure 5C ). Indeed, BRD4 knockdown increased the osteoblastic differentiatiation as revealed by a greater mineralized surface and a stable expression of hRUNX2 ( Figure 5C ).
BET protein inhibition slightly increases normal bone mass without affecting its mechanical properties
We tested whether BET protein inhibition could affect the normal bone architecture. Healthy 
BET protein inhibition decreases osteoclast number in vivo
Histomorphometric analysis of trabecular bone in the proximal tibia showed a significant decrease in osteoclast number in JQ1 treated animals (Oc.N.; Figure 7A ). The number of and bone formation (BFR/BS (µm 2 /µm 3 /day)) in physiological conditions.
Discussion
According to the world health organization, osteoporosis affects more than 75 million people in the United States, Europe and Japan and the lifetime risk of fracture has been estimated to be between 30 and 40% in developed countries. The treatment of this disease is considered essential to the maintenance of health and quality of life because of its morbid consequences.
Emerging evidences suggest that epigenetic modulations play an important role in bone biology and may offer new targets to treat bone diseases [5, 23, 24] . Thus, BET proteins are a group of epigenetic regulators that bind to acetylated lysine on histone tails to regulate chromatin accessibility to transcription factors and RNA polymerase [7, 8] . Numerous smallmolecule were developed to target BET proteins in pre-clinical models of cancers especially in hematological malignancies [9, 10, 12, [25] [26] [27] [28] . Currently, some BET protein inhibitors are being tested in early phase clinical trials illustrating the therapeutic potential of this new class of drugs (clinicaltrials.gov references NCT02157636, NCT02259114, NCT02158858 and NCT02308761). In this context, we recently showed that, JQ1, one of the BET protein inhibitor was able to suppress osteosarcoma mediated bone remodeling in a preclinical model [11] . Since then, several studies have shown that BET protein inhibition seems to be a potential candidate for the treatment of bone related diseases associated with inflammation [14] [15] [16] .
Here we report data to support and confirm that BET protein inhibition could be a promising treatment for osteoporosis. We directly challenged an existing ovariectomyinduced osteopenia and rescued it using JQ1. This preclinical study demonstrates the potential of JQ1 as curative treatment in ovariectomized mice with established bone loss, leading to a greater trabecular bone volume (both in long bones and vertebra) associated with a greater bone strength after only 28 days of treatment. These results corroborate recent studies
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demonstrating that various BET protein inhibitors could increase bone mass in rheumatoid arthritis, periodontitis and osteoporosis preclinical models [14] [15] [16] .
Histomorphometric observations revealed a decrease of osteoclast number in OVXmice at the end of experiment which could be explain by a massive reduction of bone parameters in cancellous bone after 6 weeks of ovariectomy. Nevertheless, histomorphometry revealed an increase of both osteoclast and osteoblast number within the cancellous bone in OVX-animal treated with JQ1 compared to vehicle treated animals. This fact may be explain by our in vitro observation showing that BET protein inhibition does not prevent pre OCs and
OCs to initiate osteoblastogenesis, suggesting that JQ1 could have a potential anabolic activity. This study over a longer culture period would confirm this observation through quantification of mineralization. We hypothesize that JQ1 can dissociate the two osteoclasts functions and inhibit its bone resorption activity whilst maintaining its osteoblast differentiation activation potential. To demonstrate in vivo that JQ1 has anabolic potential in OVX mice, another in vivo experiment might be performed using calcein labeling at different time points of the experiment to assess bone formation. This hypothesis is supported by Karsdal et al. who report data supporting the possibility of un-coupling bone resorption and bone formation, with OCs presenting anabolic factors even if their resorption activity is inhibited [29] . Patients suffering from osteopetrosis with mutations in the chloride channel of the osteoclast proton pump are excellent examples of this phenomenon. Indeed, those patients have reduced bone resorption associated with increased bone formation and not the classical secondary decrease in bone formation normally observed with classical anti-resorptive molecules [30] . Moreover, those patients present an increased number of non-resorbing OCs associated with an increased number of active OBs, exactly as we observed after JQ1 treatment [31] .
In the present study, we confirmed that intraperitoneal injection of JQ1 did not exert any adverse effect especially on normal bone [15, 32] . A moderate increased bone mass was observed without affecting any bone strength parameters. Histomorphological analysis of healthy mice revealed an early decrease in osteoclast numbers without any change in osteoblast number explaining the increase of bone mass. Thus, we could consider that BET protein inhibition has an effect on bone remodeling only in bone disorders such as in osteoporosis.
Mechanistically, our study confirms that BET protein inhibition induces an inhibition of both osteoclast differentiation and activity as well as of osteoblasts in vitro [11, 25] .
Interestingly, we did observe the same effects after BRD2, BRD3 and BRD4 silencing together with shRNAs confirming the central role of the BET proteins in bone cells differentiation and activity. However, the specific BRD4 silencing in human mesenchymal stem cells results in a greater mineralization which could be mediated by BRD2 and BRD3 in substitution for Brd4 and thus regulating genes that are usually activate by BRD4. This hypothesis has to be tested by ChIP for BRD2 and BRD3. The specific silencing of BRD2 and BRD3 caused both disruption of osteoblast and osteoclast differentiation. Thus, considering the higher affinity of JQ1 for BRD4, it appears that BRD4 is the key BET protein targeted by JQ1 in bone biology, exerting specific activity on bone cells. Emerging evidences are considering the activity of BRD4 as a regulator of lineage specific gene associated with enhancer elements [33] . Moreover, aging is widely associated with the accumulation of molecular defects over time and alteration of the normal epigenetic pattern. In this context, it has been suggested that an aging associated disorder such as osteoporosis could have an important epigenetic component. [5, 34] . Thus, we could consider that in bone related disorders, the activity of BRD4 is modified in bone cells leading to an inhibition of bone formation and activation of bone resorption. JQ1, as a specific inhibitor of BRD4, would blocking these mechanisms, and consequently increase bone mass. It is suggested by ParkMin who showed that BRD4 binds to the promoter of NFATc1, the master transcription factor of osteoclastogenesis, which is displaced with I-BET151 and thus decrease of NFATc1 expression [14] . We did observe similar decrease of NFATc1 expression with JQ1.
In conclusion, BET protein inhibitors result in a decrease in osteoclast differentiation and activity but do not affect their potential to activate osteoblasts. Furthermore, we show that blocking BET protein signaling with JQ1 administration can reverse the bone loss that occurs with estrogen deficiency through increases in bone mass, structure and strength. This robust response suggests that inhibition of BET protein signaling with JQ1 represents a promising new therapeutic approach for the treatment of bone-related disorders. 
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